introduction
Colon tumors with transserosal invasion (T4a) have an increased risk for the development of peritoneal carcinomatosis (PC), secondary to the intraabdominal exfoliation of cancer cells that invaded the full-thickness colonic wall and its investing serosa. Shepherd et al. pointed out the significance of transserosal invasion, with local peritoneal involvement (LPI) as a significant risk factor for intraperitoneal disease recurrence in colorectal cancer (CRC) [1] [2] [3] [4] . This is in agreement with the findings of Newland et al.
[Australian clinico-pathological staging (ACPS) group], who demonstrated a poor prognosis in rectal cancer with free serosal surface involvement [5] . Also, Park et al. showed that the depth of bowel wall invasion is a significant risk factor for prognosis in colon and rectal cancer [6] . In a critical reflection on Shepherd's findings, Williams et al. proposed to consider the use of intraperitoneal therapy for patients in this setting [4, 7] . As such, 'adjuvant' hyperthermia and intraperitoneal chemotherapy (HIPEC) could be a strategy to reduce the risk of PC and increase survival in stage II and III T4a patients. This clinical study aims to assess the burden of PC in T4 tumors and the risk for local intraperitoneal recurrence as the only site of metastatic disease. This is crucial to adequately estimate the potential benefits of HIPEC as an adjuvant treatment strategy in T4 patients. Current literature on this issue is scarce.
patients and methods
A retrospective analysis of prospectively collected data on 379 consecutive patients who underwent elective or emergency surgery for colon cancer between January 2004 and January 2007 at the department of abdominal surgery of the University Hospitals Leuven was carried out.
As a primary end point, this study focused on the metachronous occurrence of PC as the sole location of tumor recurrence in colon cancer. The secondary end point was the calculation of a power analysis if one would aim to start a prospective randomized trial to prove the impact of adjuvant HIPEC on T4a colon cancer.
The trial protocol was approved by the local medical ethics committee. The pathology report of every single resection specimens was revised by one of the authors (DH). Pathologic staging was carried out according to the American Joint Committee on Cancer (AJCC) Colon and Rectum Cancer Staging (7th edition) [8] .
According to a strict standard in-hospital protocol, patients were seen postoperatively at the outpatient clinic for oncological follow-up (FU): every 3 months in the first 2 years after surgery, every 6 months in the following 2 years and once a year from the fifth postoperative year on. At each visit, a blood sample was taken to determine the carcinoembryonic antigen (CEA) level and imaging in the form of a chest X-ray and liver ultrasound and/or CT thorax/abdomen was carried out to screen the patient for recurrent disease. At least one CT thorax/abdomen per year was carried out. All patients with suspicion of peritoneal disease underwent a PET/CT-scan to rule out systemic recurrence in and outside of the peritoneal cavity. Colonoscopy was repeated every 2 to 3 years to assess local recurrence and/or metachronous primary colonic cancer. At closing date of the study (16 September 2010) , no patients were discharged from follow-up, but 46 patients (12%) were lost to follow-up.
statistical methodology
The Kaplan-Meier (KM) estimates are used to create a curve for the percentage overall survival (OS) as a function of the time since HIPEC surgery. A log-rank test is used to compare stage II and III patients. A multivariable Cox regression is used to evaluate this difference after correction for age, sex, and postoperative chemotherapy. The hazard ratio (HR) and 95% confidence interval (CI) are reported. To construct the curves for percentage relapse and for PC, cumulative incidence estimates are used instead of KM estimates [9] . Censoring the deceased patients without respectively relapse and PC in the KM curve inappropriately assumes that those patients are still at risk after their death. To evaluate the relation between PC and OS, an extended Cox regression model is used, with PC as a binary non-reversible time-dependent covariate [10] . The length of follow-up is calculated using a KM estimate censoring the deceased patients [11] . P values are considered significant if smaller than 0.05. Analyses have been carried out using SAS software, version 9. Relapse was defined as the development of local recurrence and/or metastatic disease, i.e. PC as well as systemic metastases. As already mentioned, the relapse analysis was restricted to patients with stage II-III colon cancer for whom the data on relapse were completely available (n = 178 patients). Based on the cumulative incidence estimates, the relapse at 5 years equals 11.4% (95%CI 5.8-17.0) for stage II and 40.0% (95%CI: 29.4-50.6) for stage III colon cancer (P < 0.001) (Figure 2A ). For 94 T3 and 7 T4 tumors (80.2%) in stage II disease and 60 T3 and 12 T4 tumors (80.9%) in stage III disease, follow-up data were completely available ( Table 2) . For T3 tumors, the relapse at 5 years equals 20.2% (95%CI 14.3-26.2) versus 40.0% (95%CI 20.8-59.2) T4 tumors (P = 0.064) ( Figure 2B) . Overall, 23 patients with T3 and T4 tumors (13.2%) without metastases (stage II and III) developed PC. Using Cox regression analysis (with PC as time-dependent predictor), PC has a significant detrimental effect on OS [HR 6.3 (95%CI: 3.0-13.0, P < 0.0001)] and there was no evidence that this effect was different for stage II and III disease (P = 0.76) (supplementary Figure S1 , available at Annals of Oncology online). Out of 14 T4a tumors 7 developed PC (50%), whereas only 1 out of 5 T4b tumors (20%) developed PC ( Table 3 ). The percentage of PC at 1 and 3 years was significantly lower for T3 tumors (4.5% and 9.3%) compared with T4 tumors (15.6% and 36.7%) (P = 0.008) (Figure 3 ). Furthermore, a higher proportion of patients with a T4 tumor (especially, T4a) developed PC as the only location of disease recurrence: only in 3 of the 15 T3 tumors with PC [ proportion (Table 2) , which is in agreement with published data, as PC is described to occur in about 12-13% of patients with CRC [12, 13] . The development of peritoneal disease recurrence will compromise survival. For unresectable PC, median survival is expected to be 3.1-9.3 months, depending on whether or not these patients are able to undergo systemic chemotherapy [14] [15] [16] . PC appears to be the only site of recurrent disease in about 25%-35% of patients [17, 18] . The understanding that peritoneal disease can occur without other metastatic locations led to the concept of a radical approach of complete cytoreductive surgery (CCRS) and HIPEC [15, [17] [18] [19] [20] . This combined treatment modality significantly increased survival, reaching a 5-year OS of 33%-51%, provided an R0/1 resection can be reached by CCRS [21] [22] [23] [24] . Shepherd et al. highlighted the prognostic importance of deep serosal invasion and LPI in CRC [1] [2] [3] [4] . The transserosal invasion of colorectal tumors (T4) was shown to increase the risk of PC and/or local recurrence [1] [2] [3] [4] . In our retrospective analysis, a clear and significant (P = 0.008) correlation was shown between the transserosal invasion of colonic cancer (T4) and peritoneal recurrence (Figure 3 ). The majority of these T4 tumors had a T4a staging (Table 3 ). In 5 of 8 T4 tumors that developed PC [ proportion 0.625, 95%CI (0.245-0.915)], PC was the only metastatic site, without synchronous systemic metastases. This could implicate that 5 out of the 19 T4 patients might eventually benefit from adjuvant HIPEC in order to prevent PC. This is 1.3% (5/379) of the total patient population presenting with colon cancer.
At present, there is no adequate diagnostic tool available to peroperatively identify tumors with transserosal invasion. A number of studies addressed the prognostic importance of detection of free intraperitoneal tumor cells (IPTC) in colorectal cancer [18, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . A review by Bleichrodt et al. [18] as well as a meta-analysis by Rekhraj et al. [25] examined several trials with various methodologies for the detection of free IPTC. They concluded that the detection of free IPTC is associated with higher local and overall recurrence and poorer prognosis [25] . Nevertheless, it should be noted that there is a tremendous variation among trials in the IPTC detection methodology and sensitivity, as well as the definition of outcome measures. Furthermore, there is often no clear information on the T-stage of the included tumors and some of the trials also included patients with stage IV disease. A large prospective trial carried out by Noura et al. aimed to evaluate the value of peritoneal lavage cytology in patients undergoing curative resection of stage I, II, or III CRC [26] . Over a time span of 13 years, 697 patients were included, 15 of whom (2.2%) had a positive cytology. Thus, apparently it takes a very large patient cohort to enable the identification of a very small number of patients at higher risk. Furthermore, there are more sensitive IPTC detection methods, such as immunocytochemistry [33] or RT-PCR [34, 35] , with detection rates of 12-47%. Nevertheless, despite this higher sensitivity, the significance of IPTC for survival remains unclear. Additionally, the ability to estimate the amount of free IPTC might have a higher clinical value than the mere detection of their presence [26] .
Assuming one would be able to peroperatively identify T4a colonic tumors, one could consider the administration of HIPEC as 'adjuvant' treatment in order to reduce the risk of peritoneal recurrence in this particular group of tumors. To our knowledge, only one study, carried out by Noura et al., explored the effects of intraperitoneal chemotherapy (IPC) with Mytomycin C (MMC) on the prevention of peritoneal recurrence in CRC in patients with positive peritoneal lavage cytology [27] . Over a time span of 20 years, 52 patients with stage II, III, or IV CRC (all T3 and T4 tumors) and positive lavage cytology were included in this trial. Thirty-one of them received an IPC perfusate with MMC, at body temperature, through a closed-abdomen technique. It is not clearly described if and how patients were randomized into both trial arms. The authors concluded that this procedure of IPC appears effective in preventing peritoneal recurrence and prolonging cancer-specific survival. Multivariate analysis showed IPC was not a significant risk factor for cancer-specific survival. For the recurrence analysis, stage IV patients were omitted. The recurrence rate was 3/24 (12.5%) in the IPC(+) group versus 6/12 (50%) in the IPC(−) group. This difference was rated significant, despite the small total number of recurrences [27] . Based on our own retrospective analysis, a sample size calculation showed that a randomized controlled trial to demonstrate the benefit of adjuvant HIPEC in stage II and III T4 colon cancers, defined as a 50% risk reduction for the development of PC without systemic metastases, with a power of 80%, would require a sample size of 352 patients. As already mentioned above, this is an impossible task for a single institute. Even with a multicentric approach inclusion of 176 stage II-III T4 colonic tumors in each trial arm would be an ambitious undertaking.
It should also be noted that there was no mortality in the trial of Noura et al. and only one patient (1.9%) was reported to have a serious adverse event related to the intraperitoneal chemotherapy [27] , whereas the combination of cytoreductive surgery and HIPEC has been extensively described to come with the price of very high morbidity [17, 22, 24, [36] [37] [38] [39] [40] [41] [42] [43] .
Finally, another important logistic remark should be added: In the first 24-72 h after surgery, fibrin tissue will inevitably be formed in the resection plane and adhesions will start to develop, thus entrapping any free IPTC that might be present in the abdomen and making them unattainable for HIPEC. Therefore, pathologic diagnosis of deep transserosal invasion should be made within 24 h after the resection.
Elias et al. agreed that, at present, the risk of developing PC has not clearly been established for patients with pT4 lesions of the colon and that the available data in the literature are discordant [24] . CCRS + HIPEC is acknowledged to result in less morbidity and mortality, as well as better survival for patients with low PCI. However, early PC is currently not detectable clinically. Thus, Elias et al. proposed to perform a second look laparotomy plus HIPEC 1 year after resection of the primary tumor for asymptomatic patients at high risk of developing colorectal PC. This high-risk population was defined based on three primary tumor-associated criteria: synchronous macroscopic PC, synchronous ovarian metastases, and perforation [24, 44, 45] . A prospective trial, including 41 patients, concluded that these selection criteria appear to be accurate. PC was found and treated with CCRS + HIPEC in 23 patients (56%), whereas the other 18 patients underwent exploration and HIPEC. This approach yielded a 5-year OS and disease-free survival of 90% and 44%, respectively [45] . Grade 3-4 morbidity was 9.7% and 1 patient died at day 69 postoperatively [45] . Based on these results, a randomized controlled trial was designed to compare this second look + HIPEC strategy with standard follow-up alone.
In conclusion, T4a colon tumors are indeed at significantly higher risk of developing PC. Furthermore, 25% (5/19) of stage II and III T4 tumors developed PC as the only site of metastases. This defines the window of opportunity for adjuvant HIPEC to prevent peritoneal recurrence. There is an urgent need to evaluate and validate diagnostic methods to allow peroperative detection of IPTC and/or transserosal invasion ( pT4a). This should allow to implement HIPEC as an adjuvant treatment in this high risk group of patients. For the time being, a strategy as proposed by Elias et al. could be the better approach. 
